RDX binds to the [GABA.sub.A] receptor-convulsant site and blocks [GABA.sub.A] receptor-mediated currents in the amygdala: a mechanism for RDX-induced seizures.
OBJECTIVE: We investigated the mechanism by which RDX induces seizures.
METHODS AND RESULTS: By screening the affinity of RDX for a number of neurotransmitter receptors, we found that RDX binds exclusively to the picrotoxin convulsant site of the [gamma]-aminobutyric acid type A ([GABA.sub.A]) ionophore. Whole-cell in vitro recordings in the rat basolateral amygdala (BLA) showed that RDX reduces the frequency and amplitude of spontaneous [GABA.sub.A] receptor-mediated inhibitory postsynaptic currents and the amplitude of GABA-evoked postsynaptic currents. In extracellular field recordings from the BLA, RDX induced prolonged, seizure-like neuronal discharges.
CONCLUSIONS: These results suggest that binding to the [GABA.sub.A] receptor convulsant site is the primary mechanism of seizure induction by RDX and that reduction of GABAergic inhibitory transmission in the amygdala is involved in the generation of RDX-induced seizures. Knowledge of the molecular site and the mechanism of RDX action with respect to seizure induction can guide therapeutic strategies, allow more accurate development of safe thresholds for exposures, and help prevent the development of new explosives or other munitions that could pose similar health risks.
KEY WORDS: amygdala, [GABA.sub.A] currents, [GABA.sub.A] receptors, RDX, seizures. Environ Health Perspect 119:357-363 (2011). doi:10.1289/ehp.1002588 [Online 10 November 2010]
Hexahydro-l,3,5-trinitro-1,3,5-triazine (RDX; royal demolition explosive) is a high-energy cyclic compound developed before World War II and has a history of worldwide use in explosive mixtures and formulations, such as C-4 (McLellan et al. 1992; Yinon 1990). RDX can be released into the environment by way of waste streams generated during the manufacture, use, and disposal of the pure product or RDX-containing munitions (McLellan et al. 1992). Another possible route of exposure is unexploded munitions found on training ranges, with the accompanying risk of groundwater leaching [Agency for Toxic Substances and Disease Registry (ATSDR) 2010]. The risk of inadvertent release to groundwater or soil has resulted in U.S. Environmental Protection Agency (EPA) regulations governing human oral exposure. Based on more recent studies (Crouse et al. 2006; Gust et al. 2009; Kasuske et al. 2009; Kucukardali et al. 2003), the U.S. EPA is currently reassessing RDX information available in the Integrated Risk Information System database (U.S. EPA 1993).
For > 60 years it has been known that human exposure to high doses of RDX causes headache, dizziness, vomiting, and confusion, followed by tonic-clonic seizures (Barsotti and Crofti 1949; Kasuske et al. 2009; Kucukardali et al. 2003). Although initial isolated reports were of accidental exposure during manufacture or other contamination (ATSDR 2010; U.S. EPA 1993), case reports peaked during the Vietnam War, when RDX was inadvertently ingested by soldiers using it to ignite cooking fires, or intentionally taken as an illicit intoxicant (Stone et al. 1969); such case reports still appear (Kasuske et al. 2009). Intense seizures and status epilepticus after experimental RDX exposure have also been observed in a wide range of species, from lizards and birds to nonhuman primates (Burdette et al. 1988; Crouse et al. 2006; Gust et al. 2009; Martin and Hart 1974; Quinn et al. 2009; Schneider et al. 1977; Von Oettingen et al. 1949). It has been speculated that the limbic plays a primary role in RDX-induced seizures (Burdette et al. 1988), but the cellular mechanism of seizure induction has been unknown. Here, we present evidence that RDX binds at the convulsant site of the [gamma]-aminobutyric acid type A ([GABA.sub.A]) receptor (Benarroch 2007; Johnston 2005; Kalueff 2007), causing reduction of [GABA.sub.A] receptor-mediated synaptic transmission and induction of epileptiform activity, as we demonstrate in the amygdala, a seizure-prone structure of the limbic system (Aroniadou-Anderjaska et al. 2007, 2008).
Materials and Methods
RDX. We obtained RDX from the Department of the Navy (Naval Ordnance and Security Activity, Indian Head, MD); HPLC analysis showed it to be > 99.5% pure, with the remainder being water. For animal experiments, RDX was dissolved in 1% methyl-cellulose and 0.2% Tween-80 and administered to rats by oral gavage at the dose of 75 mg/kg, a dose that consistently induces seizures within 30 min after administration (McCain W, personal communication). Control rats received a vehicle solution that consisted of 1% methylcellulose and 0.2% Tween-80 without RDX; vehicle was also administered by oral gavage. For in vitro studies, RDX was dissolved in dimethyl sulfoxide (DMSO) at a 100x concentration to minimize the percentage of DMSO in the final dilution.
In vivo electrophysiological experiments. Male Sprague-Dawley rats were individually housed in an environmentally controlled room (20-23[degrees]C; 12-hr light/dark cycle, with lights on 0600 hours), with food and water available ad libitum. The rats weighed 150-250 g at the beginning of the experiments. All animal experiments were approved by the Institutional Animal Care and Use Committee of the U.S. Army Center for Health Maintenance and Preventive Medicine and the Uniformed Services University of the Health Sciences. The investigators adhered to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources 1996), which requires humane treatment of all animals, with regard for alleviation of suffering.
Rats were anesthetized with a combination of ketamine [80 mg/kg, intraperitoneally (IP)] and xylazine (10 mg/kg, IP), and cortical stainless steel electrodes (Plastics One, Roanoke, VA) were stereotaxically implanted over the left and right frontal cortex (2.0 mm posterior and 2.5 mm lateral to bregma) and left and right parietal cortex (5.5 mm posterior and 2.5 mm lateral to bregma), with a reference electrode implanted over the cerebellum (1.5 mm posterior from lambda). After 1 week of recovery, rats were placed in the electroencephalogram (EEG) chamber and connected to the ERG system (Stellate, Montreal, Canada). Video-EEG recordings of baseline activity in the freely moving rats began at least 10 min before oral dosing of RDX. Both the control and RDX-dosed rats were monitored for up to 3 hr after dosing.
Measurements of in vivo acetylcholinesterase (AChE) and RDX concentrations. Rats were administered vehicle or RDX as described above. At the time of seizure onset, the rats were euthanized and samples of frontal lobe and blood were taken for measurements of AChE activity and content of RDX. We determined AChE activity in frontal cortex homogenates using the 96-well microplate method of Padilla et al. (1998). A 2% (wet wt/vol) homogenate was made in 0.1 M Na-phosphate buffer (pH 8.0) plus 1% Triton, using a 20-sec burst (on ice) of a Polytron AJ 10/35 (Brinkman Instruments, Rexdale, Ontario, Canada). Total cholinesterase [brain cholinesterase is 95% AChE (Padilla et al. 1998)] was determined at 37[degrees]C by measuring the change in absorbance at 412 nm over 5 in in a 96-well plate reader (Bio-Tek Synergy HT, Winooski, VT) using acetylcholine iodide as substrate and 5,5'-dithio-bis[2-nitrobenzoic acid] as the colorimetric indicator. We generated a glutathione sulfhydryl standard curve for conversion of absorbance units into nano-moles of sulfydryl groups. AChE enzymatic activity in the brain samples was then calculated as micromoles of substrate hydrolyzed per minute per gram wet weight (ww) (Padilla et al. 1998). Blood and brain samples were assayed for RDX content by the U.S. Army Public Health Command Directorate of Laboratory Sciences using gas chromatography with electron capture detection (GC-ECD) (Bishop et al. 2003).
Receptor binding assays. Neurotransmitter receptor binding assays for RDX were performed by Ricerca Biosciences (Concord, OH). The specific assays and catalog numbers are listed in Table 1. Initially, RDX was tested at a single concentration of 33 [micro]M. Routine screening for receptor affinity is usually done with a compound concentration of 10 [micro]M (Ricerca Biosciences). To better ensure the probability of a "hit" with RDX, the initial test of RDX was performed using 33 [micro]M, a half-log higher concentration. Subsequently, a complete dose response of RDX was tested in the [[.sup.35]S]-t-butylbicyclophosphoorothionate ([[.sup.35]S]-TBPS) convulsant site assay (catalog no. 226830) using picrotoxin as standard; this assay is based on the method of Maksay (1993). The maximal inhibitory concentrations ([IC.sub.50]) were determined by a nonlinear least-squares regression analysis using MathlQ (ID Business Solutions Ltd., Guildford, Surrey, UK). The inhibition constant ([K.sub.i]) values were calculated using the equation of Cheng and Prusoff (1973), the observed [IC.sub.50] of the tested compound, the concentration of radioligand employed in the assay, and the historical values for the dissociation constant ([K.sub.D]) of the ligand (obtained experimentally at Ricerca Biosciences).
Table 1. List of binding assays screened for affinity of RDX. Catalog no. Receptor/binding site Percent inhibition 235010 Glutamate, nonspecific 7 232600 Glutamate. AMPA -10 233000 Glutamate, NMDA, phencyclidine 2 258590 Nicotinic acetylcholine 9 254000 Muscarinic, nonselective, central 7 239000 Glycine, strychnine sensitive 2 279510 Sodium channel, site 2 16 228510 GABA. nonselective 4 226810 [GABA.sub.A], chloride channel, TBOB 76 (a) 226830 [GABA.sub.A], chloride channel, TBPS 78 (a) 226600 [GABA.sub.A], flunitrazepam, central 5 226500 [GABA.sub.A], muscimol, central 13 203500 Adrenergic [[alpha].sub.1], nonselective -11 203900 Adrenergic [[alpha].sub.2], nonselective -5 260500 Opiate, nonselective 7 226700 Peripheral benzodiazepine receptor -6 268700 Purinergic [P.sub.2X] 10 271000 Serotonin 5-[HT.sub.1], nonselective 26 271200 Serotonin 5-[HT.sub.1B] -5 271910 Serotonin 5-[HT.sub.3] -9 272000 Serotonin 5-[HT.sub.4] 12 279510 Sodium channel, site 2 -5 220320 Transporter, dopamine (DAT) 0 204410 Transporter, norepinephrine -6 274030 Transporter, serotonin (SERT) -5 Catalog numbers are from Ricerca Biosciences. (a) Met criteria for significance.
In vitro extracellular and whole-cell patch-clamp recordings. Acute amygdala slices were prepared from male Sprague-Dawley rats (200-250 g body weight) as described previously (Aroniadou-Anderjaska et al. 2001; Braga et al. 2003). The artificial cerebrospinal fluid (ACSF) consisted of 125 mM NaCl, 2.5 mM KC1, 2.0 mM [CaCl.sub.2], 1.0 mM [MgCl.sub.2], 25 mM [NaHCO.sub.3] 1.25 mM [NaH.sub.2][PO.sub.4], and 11 mM glucose, bubbled with 95% [O.sub.2]/5%[CO.sub.2] to maintain a pH of 7.4. For extracellular field potential recordings, slices were transferred to an interface-type recording chamber maintained at 32[degrees]C, where they were perfused with ACSF at 0.7-1 mL/min. Spontaneous activity was recorded in the basolateral amygdala (BLA) in the gap-free mode (continuous recordings), while evoked field potentials were sampled by delivering single stimulation pulses to the external capsule at 30-sec intervals. Recording glass pipettes were filled with ACSF and had a resistance of approximately 5 M[OMEGA]. Bipolar stimulating electrodes were constructed from twisted stainless steel wire, 50 [micro]m in diameter. Spontaneous and evoked analog signals were digitized using pClamp10 software (Molecular Devices, Division of MDS Analytical Technologies, Sunnyvale, CA).
For whole-cell recordings, slices were transferred to a submersion-type recording chamber (0.7 mL volume), where they were continuously perfused with oxygenated ACSF at a rate of 3-5 mL/min. The techniques employed were similar to those described previously (Braga et al. 2003; Pidoplichko and Dani 2005). All experiments were performed at 32-33[degrees]C. We visualized neurons under infrared light using Nomarski optics of an upright microscope (Zeiss Axioskop 2; Carl Zeiss Microimaging, Thornwood, NY) equipped with a CCD-100 camera (Dage-MTI, Michigan City, IN). Tight-seal (> 1 G[OMEGA]) whole-cell recordings were obtained from the cell body of pyramidal-shaped neurons in the BLA region. Access resistance (5-24 M[OMEGA]) was regularly monitored during recordings, and cells were rejected if the resistance changed by &g; 15% during the experiment. Patch electrodes were fabricated from borosilicate glass and had a resistance from 3 to 4 M[OMEGA] when filled with solution A (60 mM [CsCH.sub.3][SO.sub.3], 60 mM KCH3SO3, 10 mM KC1, 10 mM EGTA, 10 mM HEPES, 5 mM Mg-ATP, 0.3 mM NaGTP, pH 7.2; 280-290 mOsm/kg) or with solution B (135 mM Cs-gluconate, 10 mM [MgCl.sub.2], 0.1 mM [CaCl.sub.2], 1 mM EGTA, 10 mM HEPES, 2 mM Na-ATP, 0.2 mM [Na.sub.3]GTP, pH 7.2; 280-290 mOsm/kg). Solution B (high [Cs.sup.+]) stabilizes cell leakage (allowing prolonged periods of recording) but depresses the hyperpolarization-activated current ([I.sub.h]), whereas solution A (lower [Cs.sup.+]) still keeps the leakage low without affecting the [I.sub.h] current. Neurons were voltage-clamped at +40 mV (intrapipette solution A) or at -70 mV (intra-pipette solution B) holding potential, using an Axopatch 200B amplifier (Axon Instruments, Foster City, CA).
We performed pressure application of GABA with the help of the push-pull experimental arrangement (Pidoplichko and Dani 2005). Pressure was applied to the pipette via a Picospritzer (General Valve Division, Parker Hannifin Corp., Fairfield, NJ), set at about 225 Pa (30 psi). A motorizer (Newport, Fountain Valley, CA) was coupled with the approach/withdrawal (push-pull) actuator of a micromanipulator (Burleigh PCS-5000 series; EXFO Photonic Solution Inc., Mississauga, Ontario, Canada). Motorizer movement and duration of application pulses were controlled with a Master-8 digital stimulator (AMPI; Jerusalem, Israel). Ionic currents were amplified and filtered (1 kHz) using an Axopatch 200B amplifier, with a four-pole low-pass Bessel filter, and were digitally sampled (up to 5 kHz). Currents were recorded using pClamp10 software (Axon Instruments) and further analyzed using OriginLab (Northampton, MA) and Mini60 software (Synaptosoft, Fort Lee, NJ).
We used the following receptor/channel antagonists during whole-cell recordings: 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an [alpha]-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)/kainate receptor antagonist; D-2-amino-phosphonovalerate (AP-5), an N-methyl-D-aspartic acid (NMDA) receptor antagonist; and SCH50911, a [GABA.sub.B] receptor antagonist, all from Tocris Cookson (Ballwin, MO). We also used bicuculline methiodide, a [GABA.sub.A] receptor antagonist, and tetrodotoxin, a sodium channel blocker, both from Sigma Chemical Co. (St. Louis, MO).
Statistical analysis. Statistical significance was determined using unpaired or paired Student's t-test. Differences were considered statistically significant when the probability for error was < 0.05. Data are presented as mean [+ or -] SE.
RDX administration induces seizure activity in vivo. We characterized RDX-induced seizures in vivo using behavioral observations and EEG recordings from surface-implanted electrodes. Rats (n = 4) were administered RDX (75 mg/kg) via oral gavage and allowed to move freely in their cages. Eleven to 16 min after RDX administration, rats presented one or more myoclonic twitches, followed by a single tonic-clonic seizure. The myoclonic twitch was accompanied, in the EEG, by a single sharp wave. We observed rhythmic, continuous, and high-amplitude polyspikes in the EEG during tonic-clonic seizures (Figure 1). This pattern of myoclonic twitches preceding a tonic-clonic seizure continued such that each rat had three or four tonic-clonic seizures within the next 1.5 hr before an episode of wild running/jumping. After the running/jumping, a final lasting tonic-clonic seizure with loss of righting reflex continued until death at 2-3 hr after RDX administration. Control rats that received only vehicle solution displayed normal behavior and normal electrographic activity.
Effects of RDX on brain AChE. Organophosphorus pesticides and nerve agents are potent inhibitors of peripheral and central nervous system AChE. Exposure to these agents causes excessive salivation and lacrimation in addition to seizure induction (Shih et al. 2003). Because of anecdotal reports of increased salivation and/or lacrimation associated with RDX intoxication (Burdette et al. 1988; Crouse et al. 2006; Schneider et al. 1977), we speculated that RDX-induced seizures might involve a similar inhibition of brain AChE. To examine this possibility, we administered RDX (75 mg/kg) or vehicle solution to rats (n = 6/group). Seizures appeared 10-21 min after dosing, but we did not observe increased salivation or lacrimation. At the onset of seizures, the rats were euthanized, and samples of the frontal lobe and blood were collected for measurements of AChE activity and content of RDX. AChE activity in the vehicle- and RDX-treated groups was identical (6.6 [+ or -] 0.4 [micro]mol/min/g ww). Thus, seizure induction by RDX does not involve inhibition of AChE.
Blood and brain concentrations of RDX during seizures. Analysis of the blood and frontal cortex samples taken at the onset of RDX-induced seizures indicated a direct correlation of blood to brain concentrations of RDX (Figure 2A); the correlation coefficient (CC) was 0.81. This result indicates that RDX readily enters the brain in direct proportion to the level of RDX in the blood after intestinal absorption. The correlation of brain RDX concentration with time to seizure onset after the oral gavage dose is presented in Figure 2B (CC = -0.61). These data indicate that the higher the brain concentration of RDX, the shorter the time interval between RDX administration and seizure onset.
RDX binds to the convulsant site of the [GABA.sub.A] receptor. To determine the binding sites of RDX in the brain that may be involved in seizure induction, we screened a battery of neurotransmitter receptors for affinity to RDX. The receptors assayed included those implicated as targets of known convulsants, such as the glutamate family of receptors, nicotinic and muscarinic acetylcholine receptors, the glycine receptor, the family of [GABA.sub.A] receptor ligand sites, the batrachotoxin site of the sodium channel (site 2) (Catterall et al. 1981), and several others (Table 1). Out of this comprehensive list, the only binding site for which RDX had significant affinity was the TBPS/picrotoxin/t-butylbicycloorthobenzoate (TBOB) convulsant site of the [GABA.sub.A] receptor (Kalueff 2007; Maksay 1993). RDX inhibited [[.sup.35]S]-TBPS and [[.sup.35]S]-TBOB binding by > 70% at the screening RDX concentration of 33 [micro]M. In Figure 3, the full dose-response [[.sup.35]S]-TBPS binding curve is shown for both RDX and picrotoxin, which was used as a positive control; RDX has an apparent [K.sub.1] of 21.1 [+ or -] 2.1 [micro]M, compared with picrotoxin, which has an apparent [K.sub.i] of 0.20 [+ or -] 0.042 [micro]M.
RDX reduces [GABA.sub.A] currents and induces seizure-like activity in the BLA in vitro. Having found that RDX binds to the convulsant site of the [GABA.sub.A] receptor, we next examined the functional consequences by determining the effect of RDX on [GABA.sub.A] receptor-mediated currents in the basolateral nucleus of the amygdala (BLA). The amygdala plays a central role in seizure generation, with the BLA being the most important nucleus involved in this role (Aroniadou-Anderjaska et al. 2007, 2008; Mohapel et al. 1996; White and Price 1993), and previous studies have suggested that the amygdala is a target for RDX (Burdette et al. 1988; Levine et al. 1990; Macphail et al. 1985). In in vitro brain slices, we identified recorded neurons in the BLA as principal cells on the basis of their pyramidal shape and the presence of a current activated by hyperpolarization ([I.sub.h] current). About 85% of amygdala neurons are principal pyramidal neurons displaying [I.sub.h] (Park et al. 2007). We detected the presence of [I.sub.h] by applying hyperpolarizing steps from the holding potential of -70 mV with 10-mV increments.
First, we examined the effects of RDX on action-potential-dependent spontaneous inhibitory postsynaptic currents (sIPSCs) recorded at holding potential ([V.sub.h]) = +40 mV (Figure 4A) with intracellular/recording pipette solution A (see "Materials and Methods") or at [V.sub.h] = -70 mV (Figure 4B) with intracellular solution B, in the presence of CNQX (10 [micro]M), AP-5 (50 [micro]M), and SCH50911 (20 [micro]M) to block AMPA/kainate, NMDA, and [GABA.sub.B] receptors, respectively. Bath application of 30 [micro]M RDX significantly reduced both the frequency and amplitude of the sIPSCs, from 21 [+ or -] 3 events/sec and 60 [+ or -] 10 pA (n = 4) in control conditions to 8 [+ or -] 2 events/sec and 31 [+ or -] 4 pA in the presence of RDX (n = 4, p < 0.05). Examples are shown in Figure 4A and B, and the group results are shown in Figure 4C and D. sIPSCs recovered only partially after 12-to 15-min washout of RDX. The recovered currents were completely blocked by the [GABA.sub.A] receptor antagonist bicuculline (20 [micro]M; Figure 4B).
To directly demonstrate the blockade of GABA currents by RDX, we examined the effect of RDX on the currents induced by local pressure application of GABA. Pressure-applied GABA (200 [micro]M) for 500 msec to pyramidal-shaped BLA neurons, in the presence of CNQX (10 [micro]M), AP-5 (50 [micro]M), and SCH50911 (20 [micro]M), elicited currents that were significantly reduced by 40 [micro]M RDX added to the bath (37 [+ or -] 3% reduction, mean + SE; n = 6; Figure 5). Current amplitudes recovered only partially after the washout of RDX.
To determine the impact of the reduction of sIPSCs by RDX on the overall activity of the BLA neuronal network, we applied RDX (100 [micro]M) to the slice medium while recording extracellular field spontaneous activity. RDX induced prolonged, seizure-like neuronal discharges in the BLA within 15-25 min after exposure (n = 4; Figure 6). We applied single-pulse stimuli every 30 sec to sample the evoked field potential responses. Seizure-like activity was triggered by each stimulus pulse but was also present when stimulation was turned off (Figure 6B, C). The effect of RDX was not reversible at least after 40 min of RDX washout.
RDX has been used extensively as an explosive in both military and civilian applications. The health hazards from RDX exposure have been known since the 1940s, with brain seizures and status epilepticus as one of the major symptoms of RDX intoxication seen in humans (Barsotti and Crofti 1949; Stone et al. 1969) and rats (Burdette et al. 1988; Macphail et al. 1985; Schneider et al. 1978; Von Oettingen et al. 1949). However, until the present day there has been no information regarding the mechanisms by which RDX induces seizures. The major finding of the present study is that RDX binds to the picrotoxin convulsant site of the [GABA.sub.A] receptor and inhibits [GABA.sub.A] receptor--mediated synaptic transmission; this is likely to be the primary mechanism by which RDX induces brain seizures.
RDX-induced seizures. Previous reports have described seizures in humans after accidental acute consumption of RDX (Hollander and Colbach 1969; Kasuske et al. 2009; Stone et al. 1969; Woody et al. 1986). Animal studies have also demonstrated the induction of seizures after RDX administration (Burdette et al. 1988; Crouse et al. 2006; Gust et al. 2009; Macphail et al. 1985; Martin and Hart 1974; Schneider et al. 1977; Von Oettingen et al. 1949). Because RDX causes rats to convulse within seconds after intravenous injection, Schneider et al. (1977) concluded that convulsions are caused by the parent compound rather than a neurotoxic metabolite of RDX. The present study supports this view because the brain concentration of RDX correlated positively with the time to seizure initiation and because RDX reduced GABAergic transmission and induced epileptiform activity in isolated brain slices. In addition, the present findings indicate that RDX is rapidly absorbed after oral administration and readily crosses the blood-brain barrier. A brain level of 8 [micro]g/g ww was the lowest level we observed in the RDX-treated rats at the time of seizure onset, implying that this brain level is adequate for seizure initiation. The variability in blood/brain RDX concentrations among animals is probably related to differential absorption of the water-insoluble RDX in the methylcellulosc suspension.
Burdette et al. (1988) suggested that the limbic system is significantly involved in RDX-induced seizures, based on the observation that amygdala kindling was accelerated in rats that received a relatively low daily dose of RDX. Here, we show that RDX reduces [GABA.sub.A] receptor--mediated inhibitory synaptic transmission in the rat BLA, producing hyper-excitability and the appearance of seizure-like neuronal discharges in vitro. Consistent with the view that the amygdala is a primary target of RDX, and the well-known role of the amygdala in startle responses (Davis et al. 2008) and aggressive behavior (Mpakopoulou et al. 2008), rats that are administered RDX and do not reach the threshold for seizures display an increased acoustic startle response (Macphail et al. 1985), as well as an overall hyperreactivity and increased fighting (Levine et al. 1990).
Mechanisms of RDX seizure induction. Many convulsants induce seizures by reducing GABAergic inhibition, either by competitively antagonizing GABA or by directly blocking chloride influx through the [GABA.sub.A] channel (Kalueff 2007; Rowlett et al. 2005). The "cage convulsants," compounds with cyclical structure, bind at a convulsant binding pocket inside the [GABA.sub.A] ionophore at different--and possibly overlapping--positions. This "binding pocket" of the [GABA.sub.A] channel is also referred to as the picrotoxin convulsant site (Ito and Ho 1994; Kalueff 2007; Maksay and van Rijn 1993). We found that RDX, a cyclical nitramine, binds to the [GABA.sub.A] receptor convulsant site but does not bind to any of the other neurotransmitter or neuromodulator receptors we studied. RDX displaced TBPS, a noncompetitive (for GABA) ionophore blocker, which acts at the picrotoxin convulsant site (Ito and Ho 1994; Kalueff 2007; Maksay and van Rijn 1993). RDX also displaced TBOB, which appears to bind at the same site as TBPS, and with kinetics similar to those of TBPS (Maksay and van Rijn 1993). Thus, RDX binds inside the chloride ionophore at a convulsant site overlapping with TBPS. The potency of RDX at the [GABA.sub.A] convulsant site ([K.sub.i] of 21.1 [micro]M) is similar to pentylenetetrazol, a convulsant commonly used in animal models of seizure and epilepsy that is also known to bind at the picrotoxin convulsant site (Coulter et al. 1990).
We tested the functional implications of RDX binding to the picrotoxin convulsant site in the amygdala, a limbic structure that plays a central role in the generation and propagation of seizures (Aroniadou-Anderjaska et al. 2008) and is a primary target for neurotoxins, including warfare neurotoxins such as nerve agents (Apland et al. 2009; Aroniadou-Anderjaska et al. 2009; Shih et al. 2003). We found that RDX significantly reduced the frequency and amplitude of action-potential-dependent sIPSCs in the BLA, the amygdala nucleus that plays the primary role in seizure generation (Aroniadou-Anderjaska et al. 2007, 2008; Mohapel et al. 1996; White and Price 1993). Consistent with the results from the binding studies described here, RDX reduced sIPSCs by a postsynaptic action on [GABA.sub.A] receptors. This is supported by the significant reduction of the postsynaptic currents evoked by locally applied GABA in the presence of RDX. The prolonged, seizure-like neuronal discharges recorded in the BLA in the presence of RDX were probably a result of the reduced inhibitory tone (reduced sIPSCs) throughout the BLA network because of the blockade of the [GABA.sub.A] channels by RDX. In a recent study in the northern bobwhite quail, Gust et al. (2009) found many molecular alterations in the brain after terminal RDX-induced seizures, including alterations in the expression of genes involved in the regulation of neuronal excitability.
RDX did not affect the activity of brain or peripheral blood AChE. The reported increased salivation and lacrimation after prolonged, low-dose RDX intoxication (Burdette et al. 1988; Crouse et al. 2006; Schneider et al. 1977) may be mediated by the effect of RDX at the [GABA.sub.A] receptor, similar to the effects of type II pyrethroid esters (Ecobichon 2001).
In the present study, we found that RDX induces seizures by binding to the picrotoxin convulsant site of the [GABA.sub.A] ionophore, thereby reducing GABAergic inhibitory transmission. We studied the effect of RDX on GABAergic synaptic transmission in the basolateral nucleus of the amygdala. Along with previous studies (Burdette et al. 1988; Levine et al. 1990; Macphail et al. 1985), the present study suggests that the amygdala is involved in the seizurogenic effects of RDX; however, other brain regions may also be significantly involved. In addition, although we performed RDX binding studies for a number of neurotransmitter and neuromodulator receptors as well as sodium channels, the list certainly is not exhaustive; RDX might also bind to other channels that affect neuronal excitability, which we did not test in the present study. The mechanism of RDX seizure induction revealed in the present study in rats is probably similar in humans, because the binding characteristics of TBPS to the [GABA.sub.A] receptor are similar in rat and human brain (Atack et al. 2007; Cole et al. 1984). Knowing that RDX induces seizures by binding to the [GABA.sub.A] ionophore can guide treatment efforts in cases of RDX overexposure and contribute to the development of drugs that will prevent the onset of seizures without producing sedation or other undesirable effects. Furthermore, with other potential munitions in development by the military, knowledge of the molecular site and the mechanism of RDX action with respect to seizure induction can help prevent the development of explosives or other munitions that could pose similar health risks.
Apland JP, Aroniadou-Anderjaska V, Braga MR 2009. Soman induces ictogenesis in the amygdala and interictal activity in the hippocampus that are blocked by a GluR5 kainate receptor antagonist in vitro. Neuroscience 159(1):380-389.
Aroniadou-Anderjaska V, Figueiredo YH, Apland JP, Qashu F, Braga MF. 2009. Primary brain targets of nerve agents: the role of the amygdala in comparison to the hippocampus. Neurotoxicology 30(5):772-776.
Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF. 2008. Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy Res 78(2-3):102-116.
Aroniadou-Anderjaska V, Post RM, Rogawski MA, Li H. 2001. Input-specific LTP and depotentiation in the basolateral amygdala. Neuroreport 12(3):635-640.
Aroniadou-Anderjaska V, Qashu F, Braga MF. 2007. Mechanisms regulating GABAergic inhibitory transmission in the basolateral amygdala: implications for epilepsy and anxiety disorders. Amino Acids 32(3):305-315.
Atack JR, Ohashi Y, McKernan RM. 2007. Characterization of [[.sup.35]S]f-butylbicyclophosphorothionate ([.sup.35]S]TBPS) binding to GABAA receptors in postmortem human brain. Br J Pharmacol 150(8):1066-1074.
ATSDR (Agency for Toxic Substances and Disease Registry). 2010. Draft Toxicological Profile for RDX. Available: http://www.atsdr.cdc.gov/toxprofiles/tp78.pdf [accessed 8 February 2011].
Barsotti M, Crofti G. 1949. Epileptic attacks as manifestations of industrial intoxification caused by trimethylenetrinitroamine (T4). Med Lav 40:107-112.
Benarroch EE. 2007. GABAA receptor heterogeneity, function, and implications for epilepsy. Neurology 68(8):612-614.
Bishop RW, Hable MA, Oliver CG, Valis RJ. 2003. The USACHPPM gas chromatographic procedures for the analysis of waters and soils for energetics and related compounds. J Chromatogr Sci 41(2):73-79.
Braga MF, Aroniadou-Anderjaska V, Xie J, Li H. 2003. Bidirectional modulation of GABA release by presynaptic glutamate receptor 5 kainate receptors in the basolateral amygdala. J Neurosci 23(2):442-452.
Burdette LJ, Cook LL, Dyer RS. 1988. Convulsant properties of cyclotrimethylenetrinitramine (RDX): spontaneous audiogenic, and amygdaloid kindled seizure activity. Toxicol Appl Pharmacol 92(3):436-444.
Catterall WA, Morrow CS, Daly JW, Brown G6. I981. Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem 256(17):8922-8927.
Cheng Y, Prusoff WH. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(231:3099-3108.
Cole LM, Lawrence LJ, Casida JE. 1984. Similar properties of [[.sup.35]S]t-butylbicyclophosphorothionate receptor and coupled components of the GABA receptor-ionophore complex in brains of human, cow, rat, chicken and fish. Life Sci 35(17):1755-1762.
Coulter DA, Huguenard JR, Prince DA. 1990. Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: GABA current blockade. Br J Pharmacol 100(4):807-813.
Crouse LCB, Michie MW, Major MA, Johnson MS, Lee RB, Paulus HI. 2006. Subchronic Oral Toxicity of RDX in Rats, Toxicology Study No. 85-XC-5131-03. Protocol No. 5131-38-02-12-01. Aberdeen Providng Ground, MD:U.S. Army Center for Health Promotion and Preventive Medicine.
Davis M, Antoniadis EA, Amaral DG, Winslow JT. 2008. Acoustic startle reflex in rhesus monkeys: a review. Rev Neurosci 19(2-3):171-185.
Ecobichon DJ. 2001. Toxic effects of pesticides. In: Casarett and Doull's Toxicology: The Basic Science of Poisons, Pt 6 (Klaassen CD, ed). New York:McGraw-Hill 785-788.
Gust KA, Pirooznia M, Quinn MJ Jr, Johnson MS, Escalon L, Indest KJ, et al. 2009. Neurotoxicogenomic investigations to assess mechanisms of action of the munitions constituents RDX and 2,6-DNT in northern bobwhite (Colinus virginianus). Toxicol Sci 110(1):168-180.
Hollander Al, Colbach EM. 1969. Composition C-4 induced seizures: a report of five cases. Mil Med 134(13):1529-1530.
Institute of Laboratory Animal Resources. 1996. Guide for the Care and Use of Laboratory Animals. Washington, DC:National Academy Press. Available: http://www.nap.edu/openbook.php?record_id=5140 [accessed 27 January 2011].
Ito Y, Ho IK. 1994. Studies on picrotoxin binding sites of GABA-A receptors in rat cortical synaptoneurosomes. Brain Res Bull 33(4):373-378.
Johnston GA. 2005. GABA(A) receptor channel pharmacology. Curr Pharm Des 11(15):1867-1885.
Kalueff AV. 2007. Mapping convulsants' binding to the GABA-A receptor chloride ionophore: a proposed model for channel binding sites. Neurochem Int 50(1):61-68.
Kasuske L, Schofer JM, Hasegawa K. 2009. Two marines with generalized seizure activity. J Emerg Nurs 35(6):542-543.
Kucukardali Y, Acar HV, Ozkan S, Nalbant S, Yazgan Y, Atasoyu EM, et al. 2003. Accidental oral poisoning caused by RDX (cyclonite): a report of 5 cases. J Intensive Care Med 18(1):42-46.
Levine BS, Furedi EM, Gordon DE, Barkley JJ, Lish PM. 1990. Toxic interactions of the munitions compounds TNT and RDX in F344 rats. Fundam Appl Toxicol 15(2):373-380.
Macphail RC, Walker QD, Cook LL. 1985. Neurotoxicity of Cyclotrimethylenetrinitramine (RDX). Fort Detrick, Frederick, MD:U.S. Army Medical Research and Development Command.
Maksay G. 1993. Partial and full agonists/inverse agonists affect [[.sup.35]S]TBPS binding at different occupancies of central benzodiazepine receptors. Eur J Pharmacol 246(3):255-260.
Maksay G. van Rijn CM. 1993. Interconvertible kinetic states of t-butylbicycloorthobenzoate binding sites of the gamma-aminobutyric acid-A ionophores. J Neurochem 61(6):2081-2088.
Martin DP, Hart ER. 1974. Subacute toxicity of RDX and TNT in monkeys. Contract no. N00014-73-C-0162; NR108-985; AD A044650. Kensington, MD:Litton Bionetics, Inc.
McLellan WL, Hartley WR, Brower ME. 1992. Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). In: Drinking Water Health Advisory: Munitions, United States Environmental Protection Agency, Office of Drinking Water Health Advisories (Roberts WC, Hartley WR, eds). Boca Raton, FL:Lewis Publishers, 133-180.
Mohapel P, Dufresne C, Kelly ME, McIntyre DC. 1996. Differential sensitivity of various temporal lobe structures in the rat to kindling and status epilepticus induction. Epilepsy Res 23(3):179-187.
Mpakopoulou M, Gatos H, Brotis A, Paterakis KN, Fountas KN. 2008. Stereotactic amygdalotomy in the management of severe aggressive behavioral disorders. Neurosurg Focus 25(1):E6;doi:10.3171/FOC/2008/25/7/E6.
Padilla S, Lassiter TL, Hunter DL 1998. Biochemical measurement of cholinesterase activity. In: Neurodegeneration Methods and Protocols (Harry J, Tilson HA, eds). Methods in Molecular Medicine Series. Totowa, NJ:Humana Press, 237-245.
Park K, Lee S, Kang SJ, Choi S, Shin KS. 2007. Hyperpolarization-activated currents control the excitability of principal neurons in the basolateral amygdala. Biochem Biophys Res Commun 361(3):718-724.
Pidoplichko VI, Dani JA. 2005. Applying small quantities of multiple compounds to defined locations of in vitro brain slices. J Neurosci Methods 142(1):55-66.
Quinn JMJ, Bazar MA. McFarland CA, Perkins EJ, Gust KA, Johnson MS. 2009. Sublethal Effects of Subacute Exposure to RDX (1,3,5-trinitro-1,3,5-triazine) in the northern bobwhite, Colinus virginianus. Environ Toxicol Chem 27(1):1266-1270.
Rowlett JK, Cook JM, Duke AN, Platt DM. 2005. Selective antagonism of GABAA receptor subtypes: an in vivo approach to exploring the therapeutic and side effects of benzodiazepine-type drugs. CNS Spectr 10(1):40-48.
Schneider NR, Bradley SL, Andersen ME. 1977. Toxicology of cyclotrimethylenetrinitramine: distribution and metabolism in the rat and the miniature swine. Toxicol Appl Pharmacol 39(3):531-541.
Schneider NR, Bradley SL, Andersen ME. 1978. The distribution and metabolism of cyclotrimethylenetrinitramine (RDX) in the rat after subchronic administration. Toxicol Appl Pharmacol 46(1):163-171.
Shih TM, Duniho SM, McDonough JH. 2003. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol Appl Pharmacol 188(2):69-80.
Stone WJ, Paletta TL, Heiman EM, Bruce Jl, Knepshield JH. 1969. Toxic effects following ingestion of C-4 plastic explosive. Arch Intern Med 124(6):726-730.
U.S. EPA (U.S. Environmental Protection Agency). 1993. Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) (CASRN 121-82-4): Carcinogenicity Assessment for Lifetime Exposure. Available: http://www.epa.gov/NCEA/iris/subst/0313.htm#carc [accessed 31 August 2010).
Von Oettingen WF, Donahue DD, Yagoda H, Monaco AR, Harris MR. 1949. Toxicity and potential dangers of cyclotrimethylenetrinitramine. J Ind Hyg Toxicol 31(1):21-31.
White LE, Price JL. 1993. The functional anatomy of limbic status epilepticus in the rat. I. Patterns of 14C-2-deoxy-glucose uptake and Fos immunocytochemistry. J Neurosci 13(11):4787-4809.
Woody RC, Kearns GL, Brewster MA, Turley CP, Sharp GB, Lake RS. 1986. The neurotoxicity of cyclotrimethylenetrinitramine (RDX) in a child: a clinical and pharmacokinetic evaluation. J Toxicol Clin Toxicol 24(4):305-319.
Yinon J. 1990. Cyclotrimethylenetrinitramine (RDX). In: Toxicity and Metabolism of Explosives. Boca Raton, FLCRC Press, 145-164.
Address correspondence to M.F.M. Braga, Department of Anatomy, Physiology, and Genetics, USUHS, 4301 Jones Bridge Rd., Bethesda, MD 20814 USA. Telephone: (301) 295-3524. Fax: (301) 295-3566. E-mail: email@example.com
This work was supported by the CounterACT Program, National Institutes of Health Office of the Director through National Institute of Neurological Disorders and Stroke award U01 NS058162-01, Defense Brain and Spinal Cord Injury Program award F170TM, and the National Defense Center for Energy and Environment through the Concurrent Technologies Corp. Additional funding came from the Office of the Assistant Secretary of the Army (Installations and Environment) and conducted under contract W74V8H-04-D-0005 Task 0615-Al through the National Defense Center for Energy and Environment, which is operated by the Concurrent Technologies Corp.
The authors declare they have no actual or potential competing financial interests.
Received 18 June 2010; accepted 10 November 2010.
Larry ft Williams, (1) Vassiliki Aroniadou-Anderjaska, (2), (3), (4) Felicia Qashu, (2) Huckelberry Finne, (4) Volodymyr Pidoplichko, (2) Desmond I. Bannon, (1) and Maria F. M. Braga (2), (3), (4)
(1) U.S. Army Public Health Command (Provisional), Aberdeen Proving Ground, Maryland, USA; (2) department of Anatomy, Physiology, and Genetics, (3) Department of Psychiatry, and (4) Neuroscience Program, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Research; hexahydro-1,3,5-trinitro-1,3,5-triazine|
|Author:||Williams, Larry R.; Aroniadou-Anderjaska, Vassiliki; Qashu, Felicia; Finne, Huckelberry; Pidoplichko|
|Publication:||Environmental Health Perspectives|
|Date:||Mar 1, 2011|
|Previous Article:||A distribution-based multiple imputation method for handling bivariate pesticide data with values below the limit of detection.|
|Next Article:||Use of in vitro HTS-derived concentration-response data as biological descriptors improves the accuracy of QSAR models of in vivo toxicity.|